Company Description

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

Country	Netherlands
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	100
CEO	Michael Davidson

Contact Details

Address: Gooimeer 2-35 Naarden, 1411 DC Netherlands
Phone	31 35 206 2971
Website	newamsterdampharma.com

Stock Details

Ticker Symbol	NAMS
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1936258
ISIN Number	NL00150012L7
SIC Code	2834

Key Executives

Name	Position
Dr. Michael Harvey Davidson FACC, Facp., M.D.	Chief Executive Officer, President and Executive Director
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.	Founder, Chief Scientific Officer, Member of Executive Board and Director
Mayur Amrat Somaiya	Chief Financial Officer

Latest SEC Filings

Date	Type	Title
Aug 25, 2026	144/A	Filing
Aug 24, 2026	144	Filing
Aug 14, 2026	8-K/A	[Amend] Current report
Aug 14, 2026	8-K	Current Report
Aug 6, 2026	SCHEDULE 13G/A	Filing
Aug 5, 2026	8-K	Current Report
Aug 5, 2026	10-Q	Quarterly Report
Jul 24, 2026	8-K	Current Report
Jul 22, 2026	8-K	Current Report
Jun 5, 2026	S-8	Securities to be offered to employees in employee benefit plans

View All SEC Filings